Retatrutide access expands, putting physicians on the front line of ‘next-gen’ GLP-1 demand
Industry Buzz
The right medication is the one a patient can tolerate, use safely, and maintain long-term ... Until it’s approved and we have labeling, dosing, safety data, and real-world experience, I can’t say that there’s an ideal patient for Reta.
—Rocio Salas-Whalen, MD, via Marie Claire
There are a lot of people out there that would absolutely clinically benefit from this drug. So why would they specifically pull out one person? That doesn’t make any sense.
—Spencer Nadolsky, MD, via STAT
An unnamed 79-year-old patient’s special access to Eli Lilly’s investigational obesity drug retatrutide raised eyebrows this summer. Now, the company says other patients can apply for early access, provided they meet specific medical criteria and cannot enroll in a clinical trial.[]
For physicians, the news is a reminder that retatrutide questions may arrive well before clinicians have a label, dosing guidance, or a clear expanded-access pathway to offer.
A limited pathway, not an early launch
Retatrutide is not FDA-approved, and Lilly is not opening routine prescribing. The company told STAT that it is reviewing provider-submitted requests for a limited number of patients for whom early access is considered medically appropriate under FDA guidance.[]
Expanded access is individualized and does not mean a patient is entitled to treatment, nor does it establish the drug’s safety or effectiveness for a particular patient outside of clinical trials.
“The right medication is the one a patient can tolerate, use safely, and maintain long-term. ... Until it’s approved and we have labeling, dosing, safety data, and real-world experience, I can’t say that there’s an ideal patient for Reta,” Rocio Salas-Whalen, MD, an obesity medicine specialist, told Marie Claire.[]
For most interested patients, trial enrollment, approved obesity drugs, and evidence-based obesity care remain the practical options.
Related: Your patient lost weight on a GLP-1. Now they’re back with all new concerns. Here’s how to respondWhy retatrutide has become obesity medicine’s next obsession
Online, retatrutide, often shortened to “Reta,” is already being positioned as “the next generation of GLP-1s,” despite its lack of FDA approval.[]
The attention is understandable. Unlike semaglutide, which targets GLP-1, and tirzepatide, which targets GLP-1 and GIP, retatrutide activates GLP-1, GIP, and glucagon receptors.[]
“There are a lot of people out there that would absolutely clinically benefit from this drug. So why would they specifically pull out one person? That doesn’t make any sense,” Spencer Nadolsky, MD, an obesity and lipid specialist physician, told STAT.[]
Its phase 3 program has produced striking weight loss results. One study found that retatrutide could help people lose 30% of body weight after 104 weeks; in trials involving people with type 2 diabetes or cardiovascular disease, the highest-dose groups lost an average of 21% and 23% after 80 weeks, respectively.[]
Those results help explain the anticipation, but they are not a substitute for an approved indication, label, or long-term safety data.
Related: When GI side effects become a liability risk: How would you manage this Ozempic patient?The physician conversation: Separate promise from the gray market
When patients ask about retatrutide in the clinic, it’s important to acknowledge why a patient is interested while clearly defining what is known and unknown.
Retatrutide’s reported adverse effects include the GI effects familiar from incretin-based therapies, including nausea, diarrhea, constipation, and vomiting.[]
Questions about the long-term impact on cardiovascular outcomes also remain unresolved; available studies were not designed to establish whether the drug reduces major cardiovascular events.[]
The more immediate safety concern may be products sold online as retatrutide. Because the drug is unapproved, clinicians cannot assume that retatrutide obtained through social media or unofficial peptide vendors is authentic, sterile, correctly dosed, or even contains retatrutide.[]
Patients may view retatrutide as the inevitable successor to Wegovy or Zepbound. Physicians can reframe it more accurately: It is a promising triple agonist still moving through the regulatory process, with limited early access for select patients, not a medication ready for routine use.
Related: Are these popular weight loss drugs wreaking havoc on your gut?